Clonidine suppression test for a reliable diagnosis of pheochromocytoma: When to use. (24th March 2022)

• Record Type: Journal Article
• Authors: Tsiomidou, Spyridoula; Pamporaki, Christina; Geroula, Aikaterini; Van Baal, Lukas; Weber, Frank; Dralle, Henning; Schmid, Kurt W.; Führer, Dagmar; Unger, Nicole
• Is Part Of: Clinical endocrinology. Volume 97:Number 5(2022)
• Page Start: 541
• Page End: 550
• Publication Date: 2022-03-24
• Subjects: catecholamines -- clonidine suppression test -- metanephrine -- normetanephrine -- pheochromocytoma; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.14724
• Languages: English
• ISSNs: 0300-0664

Abstract

Abstract: Objective: In clinical practice, false‐positive results in biochemical testing for suspected pheochromocytoma/paraganglioma (PPGL) are not infrequent and may lead to unnecessary examinations. We aimed to evaluate the role of the clonidine suppression test (CST) in the era of analyses of plasma‐free metanephrines for the diagnosis or exclusion of PPGL in patients with adrenal tumours and/or arterial hypertension. Design and Methods: This single‐centre, prospective trial investigated the use of CST in 60 patients with suspected PPGL associated with out‐patient elevations of plasma normetanephrine (NMN) and/or metanephrine (MN), in most cases accompanied with hypertension or an adrenal mass. Measurements of plasma catecholamines and free metanephrines were performed by liquid chromatography with electrochemical detection and tandem mass spectrometry, respectively. Results: Forty‐six patients entered final analysis ( n = 20 with PPGL and n = 26 with a nonfunctional adrenal mass and/or hypertension). CST reliably excluded false‐positive baseline NMN results with a specificity of 100%. The sensitivity of CST improved from 85% to 94% when tumours with isolated MN increase ( n = 3) were not considered. In patients with elevated baseline NMN ( n = 24), CST correctly identified all patients without PPGL. Patients with falsely elevated baseline NMN results ( n = 7, 26.9%) exhibited increases of baseline NMN up to 1.7‐fold above the upper reference limit. Conclusion: CST qualifies as a useful diagnostic tool for differential diagnosis of borderline elevated plasma‐free NMN in patients with suspected PPGL. In this context, CST helps to correctly identify all false‐positive NMN screening results.